Christian Jørgensen (born 1959) has a MSc.Econ. degree from the University of Copenhagen, Denmark and an MBA from INSEAD in France. Christian spent the last 14 years of his career in leading public medical device and pharmaceutical companies. Christian was President Europe for the Chicago based multinational Hill-Rom based in The Netherlands. Prior to this he lived in Switzerland, where he served as General Manager Western Europe for US healthcare company Baxter. Christian’s first encounter with the healthcare industry was in 2004 as EVP global sales and marketing for the Danish medical device company Coloplast. Christian has also had positions as EVP one of the biggest Nordic media companies Egmont as well as CEO of the start-up mobile operator “3” in Denmark (co-owned by Investor from Sweden and Hutchison-Whampoa from Hong Kong) as one of its first employees. In between the various corporate assignments Christian has worked with aquilo consulting – a consulting company specialized in the healthcare sector. Outside these positions, Christian have had numerous board positions in public as well as PE owned companies. Christian holds 77,000 shares and right to receive 500,000 options in Biotec Pharmacon.
Børge (born 1975) assumed the position as CFO on Oct 1, 2014. He has previous experience from the position as SCM Manager at Subsea 7, and before that as CFO in Front Exploration and as Managing Director of Troms Kraft Invest. Børge holds a Master’s Degree in Business and Administration from the University of Wyoming. Børge holds 25,428 shares and 35,000 options in Biotec Pharmacon.
Rolf (born 1959) holds a M.Sc. in biology and a Ph.D in biochemistry from the University of Tromsø, where he was employed as researcher from 1988 to 1998. Since 1999 he has held the position as R&D manager in Biotec Pharmacon. In September 2006 he was appointed CSO. Number of shares in Biotec Pharmacon held by Rolf: 550,774. Number of options in Biotec Pharmacon held by Rolf: 40,000.
Jethro HolterManaging Director, ArcticZymes AS
Jethro (born 1972) joined ArcticZymes as Managing Director on January 1st, 2015. He has previous experience from Life Technologies (Thermo Fisher Scientific) in international business development of B2B/OEM solutions with Diagnostic and Life Science companies as well as other sales experience. Earlier in his career, he was R&D Director at Mole Genetics AS developing automated sample prep solutions. Jethro holds a Ph.D in Molecular Neuroscience from Cardiff University, UK. Number of shares in Biotec Pharmacon held by Jethro: 564. Number of options in Biotec Pharmacon held by Jethro: 40,000.
Finn KetlerVice President, Wound Care
Finn Ketler (born 1962) has a M.Sc. degree from Aarhus Business School. Finn has a long and extensive background within medical devices and wound care. He spent 14 years in Coloplast with various roles of increasing responsibility, amongst others managing Coloplast's wound care division. Finn Ketler listed the Swedish medical device start-up Vigmed at Nasdaq First North in Stockholm as a CEO. Finn is acting as a Selection Committee member in BioInnovation Institutes (BII) Incubation programme. Dinn holds 0 shares and options in Biotec Pharmacon.